Bufotenine (1, 5-hydroxy-N,N-dimethyltryptamine) was isolated from seeds of Anadenanthera spp., a tree widespread in the Brazilian cerrado, using an efficient acid-base shakeout protocol. The conversion of bufotenine into N,N-dimethyltryptamine (4) and 5-methoxy-N,N-dimethyltryptamine (5) was accomplished through an innovative and short approach featuring the use of novel bufotenine-aminoborane complex (7). Furthermore, an easy methodology for conversion of bufotenine into 5-hydroxy-N,N,N-trimethyltryptamine (6) was well-established. This is the first study that highlights bufotenine as a resource for the production of N,N-dimethyltryptamines for either pharmacological and toxicological investigations or for synthetic purposes.
The narcotic snuff (cohoba) of Piptadenia ssp. has been used in syncretic religious ceremonies in Central and South America since ancient times [1] , even though bufotenine (1, HDMT) was first isolated in 1954 from seeds of P. peregrina Benth (Anadenanthera peregrina L. Speg.) by Stromberg [2] . HDMT together with some related indoleamines and corresponding N-oxides were isolated from P. peregrina and related species [3] . Fellows and Bell [4] studying indole metabolism in P. peregrina showed an unusual direct enzymatic hydroxylation of tryptamine (2) to serotonin (3), suggesting the latter as the biosynthetic precursor of HDMT instead of DMT (4) ( Table 1 ). The occurrence and quantitative detection of 1 in other vegetal sources, such as hardinggrass (Phalaris spp.) [5] , takini, a shamanic potion from latex of Brosimum acutifolium [6] , and Citrus species [7] were also reported. Furthermore, HDMT has been found in three arboreal amphibian species of the Osteocephalus (O. taurinus, O. oophagus, and O. langsdorffii), as well as in the marine invertebrate Paramuricea clavata [8]. [10] . It is noteworthy that patients with mental illnesses such as autistic spectrum disorder (ASD) and schizophrenia have exhibited significant urinary levels of HDMT, suggesting that this alkaloid plays a role in ASD and schizophrenia and may be correlated with hyperactivity scores in autism [11] . Interest in the metabolism and pharmacokinetics, plus understanding the mechanism of action, of tryptamine derivatives has been growing in recent years, mostly for antipsychotic drugs that act directly on the serotonin 2A receptor (5-HT 2A ). Studies for mapping the binding site pocket of the 5-HT 2A receptor revealed its high affinity for serotonergic ligands HDMT and LSD [12] . Investigations using recombinant cytochrome P 450 isoenzymes showed that MDMT acts as a nonselective 5-HT agonist and causes many physiological and behavioral changes. Besides, it is O-demethylated by polymorphic CYP2D6 to generate HDMT, a metabolite more potent than DMT [13] . Latterly, it was demonstrated that coadministration of the monoamine oxidase A (MAO-A) inhibitor, harmaline, increases systemic exposure to MDMT and HDMT. These data provided a fused model including the inhibition of MAO-A-and CYP2D6-catalyzed MDMT metabolism by harmaline to describe blood harmaline, DMT, and HDMT PK profiles [14] . The synergistic action of these alkaloids is considered to be the basis of the psychotropic action of ayahuasca [15] , a beverage that has been officially incorporated in rituals of religious groups in Brazil to facilitate self-knowledge and introspection, deserving the attention of researchers [16] . Up-todate, the hallucinogen DMT was identified as a potent endogenous agonist for the sigma-1 receptor [17] and more recently it was shown to inhibit the indolethylamine-N-methyltransferase (INMT) responsible for the transfer of one or more methyl groups to small molecules such as endogenous indole-containing compounds, through a mixed competitive and noncompetitive mechanism [18] .
This work describes a different protocol for the isolation of bufotenine (1) from seeds of Anadenanthera spp., a widespread tree of the Brazilian cerrado, and focuses on the synthesis of DMT (4) and MDMT (5) starting with 1.
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Preliminary extractions of bufotenine from seeds of Anadenanthera were carried out in full accordance with the literature [2] , which yielded the alkaloid in about 1%. The requirement to collect 1 in sufficient quantity for pharmacological studies, as well as to access synthetic routes designed for N,N-dimethyltryptamines, encouraged us to improve the extraction methodology. As pointed out in the experimental section, using a modified version of the classic acidbase shakeout method and avoiding chlorinated organic solvents, bufotenine was selectively extracted in 2.4% from A. colubrina and 4% from A. peregrina (greater than the above described). The HR-ESIMS of 1 showed a quasi-molecular ion peak at m/z 205.1335 [M + H] + corresponding to the formula C 12 H 17 N 2 O. 1 H-, 13 C-and twodimensional (COSY, HMQC and HMBC) NMR experiments were also used to accomplish bufotenine identification. The 1 H and 13 C NMR assignments are given in Table 2 , in accordance with the numbered structure. Scheme 1 outlines our approach to the synthesis of the title compounds. After several attempts, 1 was first over N-methylated in mild conditions (without basic catalysis) furnishing 5-hydroxy-N,N,N-trimethyltryptamine (6) in 85%, after crystallization from acetone. However our efforts to convert this ammonium salt into DMT (4) failed in the final step, which was selective mono N-demethylation. To overcome this limitation, 1 was converted into an aminoborane complex (7) with borane-dimethyl sulfide. Then, DMT (4) was prepared in 39% overall yield from 7 by transforming the 5-OH group into an O-Tf moiety, which was removed by catalytic hydrogenation. The aminoborane complex (7) was treated with iodomethane under PTC (KOH powder, TBAB in dried THF), followed by protection of the indole amine group with Boc to afford 8. The latter was subsequently treated with DABCO and TFA for removal of both protecting groups, furnishing MDMT (5) in 69% overall yield (Scheme 1). All intermediates and targets covered in the synthetic path were characterized by HR-ESIMS, IR-FT and 1 H and 13 C plus two-dimensional (COSY, HMQC, HMBC) NMR experiments. Table 3 shows the 13 C NMR assignments for 4 to 8.
The HR-ESIMS of 6 showed an ion peak at m/z 219.1493 [M + H] + , corresponding to the formula C 13 H 20 N 2 O. The structure of 6 could be determined based on characteristic signals at δ H 3.16 (9H, s) and δ C 52.6 (3C) relative to the methyl group by comparison with those of 1 at δ H 2.27 (6H, s) and δ C 45.2 (2C).The aminoborane complex (7) was established from the ion peak at m/z 241.1495 corresponding to the [M + Na] + ion. Its IR spectrum exhibited bands at 2388, 2313 and 2279 cm -1 (borane group). The 1 H and 13 C NMR spectra of compound 7 were rather similar to those of 1, except for chemical shifts related to methylene and methyl groups. The structure of the novel derivative was further confirmed by X-ray crystallographic methods (Figure 1 ). and MDMT (5) . Furthermore, bufotenine was effortlessly converted into an aminoborane complex (7) and trimethyl ammonium salt (6) . As far as we know, this is the first time that such protocols are reported, including the description of the aminoborane complex (7) . The synthesized dimethyltryptamines will serve as analytical standards for future pharmacological studies. 
Extraction and isolation of bufotenine (1):
Air-dried seeds of Anadenanthera species (50 g) were powdered in a domestic blender and defatted with n-hexane (80 mL x 3) under magnetic stirring for 2 h at 25°C. After filtering, the residual solid was extracted with MeOH (80 mL x 4) with magnetic stirring for 2 h at 25°C. The filtered methanolic extract was concentrated in vacuum to 80 mL and diluted with H 2 O (100 mL). The resulting mixture was stirred for 2 h with aqueous 2 M HCl (40 mL), neutralized with solid Na 2 CO 3 (7.0 g), and extracted with AcOEt (20 mL x 10). The combined extract was dried over Na 2 SO 4 and evaporated in vacuum to afford a brown amorphous solid, which was recrystallized from Hydroxy-N,N,N-trimethyltryptamine (6) : A mixture of 1 (0.204 g, 1.0 mmol) and iodomethane (0.283 g, 2.0 mmol) in acetone (3.0 mL) was stirred at 25°C for 3 h, under N 2 . Then the solvent was evaporated in vacuum and the residual solid was recrystallized from acetone to give 6 (amorphous yellowish solid, 0.186 g, 85% 
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Bufotenine-aminoborane complex (7):
To a solution of 1 (1.02 g, 5.0 mmol) in THF, dried prior to use, was added 10 M Me 2 S-BH 3 in THF (0.75 mL, 7.5 mmol). The mixture was stirred at 0°C for 2 h, under N 2 . After concentration, the residue was dissolved in CH 2 Cl 2 (40 mL). The organic layer was washed with 10% aqueous NH 4 OH (100 mL x 3), dried over Na 2 SO 4 , and evaporated in vacuum. CC (n-hexane:AcOEt 2:1) of the residue afforded 7 (white crystals, 1.03 g, 95%). R f : 0.3 (n-hexane- Crystal data for complex (7) : Crystallographic measurements were collected on a Bruker CCD SMART APEX II single crystal diffractometer with Mo Kα radiation (0.71073 Å) at 296K, processed with SAINT and corrected for absorption using SADABS [20] . Experimental data can be found on file deposited at the Cambridge Crystallographic Data Centre with CCDC number 1022431. The structures were solved by Direct Methods using SHELXS-97 and subsequent Fourier-difference map analyses yielded the positions of the non-hydrogen atoms; the refinement was performed using SHELXL-97 [21] . Molecular graphics, ORTEP-3, software were used to prepare material for publication, WinGX-Routine. Table 3 .
N,N-Dimethyltryptamine (4):
5-Methoxy-N-Boc bufotenine-aminoborane complex (8):
5-Methoxy-N,N-dimethyltryptamine (5):
A mixture of 8 (90 mg, 0.3 mmol) and DABCO (0.07 g, 0.6 mmol) in CH 2 Cl 2 (4.0 mL) was stirred at 25°C for 2 h, under N 2 . The mixture was diluted with CH 2 Cl 2 (10 mL), washed with H 2 O and brine, dried over Na 2 SO 4,  and evaporated in vacuum. The residue was stirred with TFA in CH 2 Cl 2 (0.5:1 mL) at 25°C. The solvent was removed in vacuum at 25°C and the residue was submitted to CC (AcOEt-Et 3 N 1:1.0x10 -3 ) to give 5 (yellow oil, 41 mg, 69% 
